David Kerstein's most recent trade in Theseus Pharmaceuticals Inc was a trade of 17,500 Restricted Stock Units done . Disclosure was reported to the exchange on March 1, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Theseus Pharmaceuticals Inc | David Kerstein | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 17,500 | 17,500 | - | - | Restricted Stock Units | |
| Theseus Pharmaceuticals Inc | David Kerstein | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Theseus Pharmaceuticals Inc | David Kerstein | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) |